Cargando…

(18)F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma

BACKGROUND: This study aimed to investigate the predictive value of (18)F‐FDG PET/CT for pathological response after neoadjuvant immunochemotherapy (NICT) in patients with esophageal squamous cell carcinoma (ESCC). METHODS: The clinical data of 54 patients with ESCC who underwent two cycles of NICT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuohua, Di, Shouyin, Lu, Jing, Xie, Shun, Yu, Zhenyang, Liang, Yingkui, Gong, Taiqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447171/ https://www.ncbi.nlm.nih.gov/pubmed/37424279 http://dx.doi.org/10.1111/1759-7714.15024

Ejemplares similares

Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study
por: Domachevsky, Liran, et al.
Publicado: (2018)

Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer
por: Huang, Shu Jie, et al.
Publicado: (2022)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Yang, Yalan, et al.
Publicado: (2023)

Diffusion-weighted MRI and (18)F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
por: Xu, Xin, et al.
Publicado: (2021)

Predictive value of clinical and (18)F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma
por: Marr, Lisa, et al.
Publicado: (2022)

(18)F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated With Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy
por: Simoni, Nicola, et al.
Publicado: (2020)

Comprehensive (18)F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study
por: Cui, Yingpu, et al.
Publicado: (2022)

(18)F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making
por: Anderegg, Maarten C. J., et al.
Publicado: (2015)

Value of (18)F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With (18)F-FDG PET/CT, MRI, and Contrast-Enhanced CT
por: Wang, Fei, et al.
Publicado: (2022)

Prognostic factors associated with (18)FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
por: Feng, Wei-Hsiang, et al.
Publicado: (2022)

Detecting Interval Distant Metastases With (18)F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

FDG PET using SUV(max) for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy
por: Huang, Yung-Cheng, et al.
Publicado: (2017)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023)

The Relationship between Pathological Features and (18) F-FDG PET/CT that Changed the Surgeon's Decision as Neoadjuvant Therapy in Breast Cancer
por: Edizsoy, Akay, et al.
Publicado: (2022)

(18)F-FDG-PET/CT-measured parameters as potential predictors of residual disease after neoadjuvant chemoradiotherapy in patients with esophageal carcinoma
por: Tustumi, Francisco, et al.
Publicado: (2022)

Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2023)

Thyroid incidentalomas on 18FDG-PET/CT: a metabolico-pathological correlation
por: Hagenimana, N., et al.
Publicado: (2017)

FDG PET/CT and Endoscopic Ultrasound for Preoperative T-Staging of Esophageal Squamous Cell Carcinoma
por: Huang, Yung-Cheng, et al.
Publicado: (2023)

Role of FDG-PET/CT in prediction of pathological tumor response and survival after trimodality therapy for esophageal squamous cell carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2015)

Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma
por: CASTALDI, P., et al.
Publicado: (2013)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

Cerebellum/liver index in pretherapeutic (18)F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance
por: Godard, François, et al.
Publicado: (2022)

Spectrum of [(18)F]FDG-PET/CT Findings in Benign Lymph Node Pathology
por: Zeman, Merissa N., et al.
Publicado: (2021)

Prognostic values of mid-radiotherapy (18)F-FDG PET/CT in patients with esophageal cancer
por: Kim, Nalee, et al.
Publicado: (2019)

Candida Esophagitis Incidentally Detected by 18F-FDG PET/CT in Metastatic Lung Adenocarcinoma
por: Martínez-Amador, N, et al.
Publicado: (2017)

Gross Tumor Delineation in Esophageal Cancer on MRI Compared With (18)F-FDG-PET/CT
por: Vollenbrock, Sophie E., et al.
Publicado: (2019)

Volumetric Evaluation of Staging (18)F-FDG PET/CT Images in Patients with Esophageal Cancer
por: Karahan Şen, Nazlı Pınar, et al.
Publicado: (2022)

Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy
por: Xia, Lianshuang, et al.
Publicado: (2023)

18F–FDG PET/CT scan confirmed by pathology findings in a singular case of squamous cell carcinoma of the epiglottis
por: Lima, G. M., et al.
Publicado: (2017)

The feasibility of (18)F-FDG PET/CT for predicting pathologic risk status in early-stage uterine cervical squamous cancer
por: Liu, Shuai, et al.
Publicado: (2020)

FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal–gastric junction
por: Fencl, Pavel, et al.
Publicado: (2016)

Dynamic (18)F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer
por: Chen, Zhi‐Yong, et al.
Publicado: (2022)

Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments
por: Song, Xin-Yun, et al.
Publicado: (2023)

(18)F-FDG PET/CT Imaging In Oncology
por: Almuhaideb, Ahmad, et al.
Publicado: (2011)

Scar Sarcoidosis on (18)F-FDG PET/CT
por: Arora, Saurabh, et al.
Publicado: (2019)

18F-FDG PET/CT and COVID-19
por: Joob, Beuy, et al.
Publicado: (2020)

Diagnostic Accuracy of Combined PET/CT with MRI, 18F-FDG PET/MRI, and 18F-FDG PET/CT in Patients with Oropharyngeal and Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Kave, Mania, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vdrtcghcm4hu57149205vl2k7i